{"id":"NCT01751867","sponsor":"Xian-Janssen Pharmaceutical Ltd.","briefTitle":"An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome","officialTitle":"An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-05","completion":"2013-04","firstPosted":"2012-12-18","resultsPosted":"2013-12-13","lastUpdate":"2016-04-05"},"enrollment":135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndrome"],"interventions":[{"type":"DRUG","name":"Decitabine at 15 mg/m2","otherNames":[]},{"type":"DRUG","name":"Decitabine at 20 mg/m2","otherNames":[]}],"arms":[{"label":"3-Day Dose schedule","type":"EXPERIMENTAL"},{"label":"5-Day Dose schedule","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) in Chinese patients.","primaryOutcome":{"measure":"Overall Response Rate (ORR): Number of Participants Who Achieved Either Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) - International Working Group (IWG) 2006 Response Criteria","timeFrame":"From the date of first dose until 30 to 42 days after the last dose of the 2 years treatment period, or at time of discontinuation","effectByArm":[{"arm":"3-Day Posology","deltaMin":10,"sd":null},{"arm":"5-Day Posology","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000","p":"0.003"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":["26568466"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":34},"commonTop":["White blood cell count decreased","Platelet count decreased","Pyrexia","Neutrophil count decreased","Haemoglobin decreased"]}}